Fredun Pharmaceuticals vs DIL vs Themis Medicare: Which Stock Should You Track

Fredun Pharmaceuticals vs DIL vs Themis Medicare starts with the core numbers most investors compare within the pharma and healthcare segment: market capitalisation, valuation multiples, profitability, dividend yield and the latest quarterly results. Figures below are sourced as of October 2026 and will shift with daily price moves.

All three names sit in the pharma and healthcare bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses. The sections below cover the company profiles, a valuation table, the latest quarter and a five-quarter trend for revenue and net profit.

Click Here – Get Free Investment Predictions

Fredun Pharmaceuticals, DIL and Themis Medicare: Company Overview

Fredun Pharmaceuticals is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 2,537 crore, a return on equity of 11.73% and a book value of Rs 162.78 per share. Its quarterly revenue moved from Rs 119.85 crore in June 2025 to Rs 228.25 crore in June 2026, a change of +90.4%.

DIL is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 1,583 crore, a return on equity of 17.67% and a book value of Rs 138.15 per share. Its quarterly revenue moved from Rs 145.03 crore in June 2025 to Rs 126.19 crore in June 2026, a change of -13.0%.

Themis Medicare is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 1,006 crore, a return on equity of 0.42% and a book value of Rs 39.74 per share. Its quarterly revenue moved from Rs 98.76 crore in June 2025 to Rs 87.95 crore in June 2026, a change of -10.9%.

Fredun Pharmaceuticals vs DIL vs Themis Medicare: Valuation and Profitability Snapshot

Metric	Fredun Pharmaceuticals	DIL	Themis Medicare
Market Cap (approx.)	Rs 2,537 crore	Rs 1,583 crore	Rs 1,006 crore
PE Ratio (TTM)	57.90	27.21	25.17
PB Ratio	9.43	3.89	2.75
Return on Equity (ROE)	11.73%	17.67%	0.42%
EPS (TTM, Rs)	26.50	19.77	4.34
Dividend Yield	0.02%	0.68%	0.46%
Debt to Equity	0.80	0.28	0.25
Book Value per Share (Rs)	162.78	138.15	39.74

Check the Univest Screener for Live Data

On valuation, Fredun Pharmaceuticals trades at a PE of 57.90 and a PB of 9.43, DIL at a PE of 27.21 and a PB of 3.89, while Themis Medicare trades at a PE of 25.17 and a PB of 2.75. On return on equity, the three post 11.73%, 17.67% and 0.42% respectively, and on dividend yield they stand at 0.02%, 0.68% and 0.46%. Fredun Pharmaceuticals has the highest market capitalisation of the three at Rs 2,537 crore, while Themis Medicare has the lowest at Rs 1,006 crore. Fredun Pharmaceuticals has the highest PE ratio of the three at 57.90, while Themis Medicare has the lowest at 25.17. DIL has the highest return on equity of the three at 17.67%, while Themis Medicare has the lowest at 0.42%. Fredun Pharmaceuticals has the highest debt to equity ratio of the three at 0.80, while Themis Medicare has the lowest at 0.25. Debt to equity is 0.80, 0.28 and 0.25 for the three respectively.

Fredun Pharmaceuticals vs DIL vs Themis Medicare: Latest Quarterly Results

Company	Latest Quarter Revenue	Latest Quarter Net Profit	YoY Change (Revenue)	QoQ Change (Revenue)	YoY Change (Net Profit)
Fredun Pharmaceuticals	Rs 228.25 crore	Rs 13.13 crore	+90.4%	+7.1%	+93.9%
DIL	Rs 126.19 crore	Rs 9.53 crore	-13.0%	-0.4%	-55.9%
Themis Medicare	Rs 87.95 crore	Rs 24.61 crore	-10.9%	+9.7%	NA

Quarterly figures above are the most recent reported quarter for each company (Q1 FY27, quarter ended June 2026), compared with the year-ago and preceding quarter. A percentage change in net profit is shown as NA where the comparison quarter was a loss or the latest quarter is a loss, since the percentage is not meaningful in that case.

Fredun Pharmaceuticals vs DIL vs Themis Medicare: Five-Quarter Revenue and Net Profit Trend

The five-quarter view below shows how revenue and net profit moved from June 2025 to June 2026 for each company in Fredun Pharmaceuticals vs DIL vs Themis Medicare, which helps separate a one-quarter move from a steadier pattern.

Quarterly revenue (Rs crore)

Quarter	Fredun Pharmaceuticals	DIL	Themis Medicare
June 2025	Rs 119.85 crore	Rs 145.03 crore	Rs 98.76 crore
September 2025	Rs 145.30 crore	Rs 135.65 crore	Rs 81.23 crore
December 2025	Rs 160.93 crore	Rs 140.48 crore	Rs 91.41 crore
March 2026	Rs 213.05 crore	Rs 126.64 crore	Rs 80.20 crore
June 2026	Rs 228.25 crore	Rs 126.19 crore	Rs 87.95 crore

Quarterly net profit (Rs crore)

Quarter	Fredun Pharmaceuticals	DIL	Themis Medicare
June 2025	Rs 6.77 crore	Rs 21.60 crore	-Rs 14.22 crore
September 2025	Rs 9.43 crore	Rs 18.03 crore	-Rs 3.62 crore
December 2025	Rs 10.48 crore	Rs 12.02 crore	Rs 10.09 crore
March 2026	Rs 10.78 crore	Rs 18.60 crore	Rs 8.89 crore
June 2026	Rs 13.13 crore	Rs 9.53 crore	Rs 24.61 crore

Fredun Pharmaceuticals reported revenue of Rs 119.85 crore in June 2025 and Rs 228.25 crore in June 2026, a change of +90.4% across the period. Its highest quarterly revenue in this window was Rs 228.25 crore in June 2026. Net profit stood at Rs 13.13 crore in June 2026, which is a net profit margin of 5.75%.

DIL reported revenue of Rs 145.03 crore in June 2025 and Rs 126.19 crore in June 2026, a change of -13.0% across the period. Its highest quarterly revenue in this window was Rs 145.03 crore in June 2025. Net profit stood at Rs 9.53 crore in June 2026, which is a net profit margin of 7.55%.

Themis Medicare reported revenue of Rs 98.76 crore in June 2025 and Rs 87.95 crore in June 2026, a change of -10.9% across the period. Its highest quarterly revenue in this window was Rs 98.76 crore in June 2025. Net profit stood at Rs 24.61 crore in June 2026, which is a net profit margin of 27.98%. Themis Medicare reported a net loss in June 2025 and September 2025.

Download the Univest iOS App or Univest Android App to track Fredun Pharmaceuticals, DIL and Themis Medicare live prices.

What Should Investors Look at Beyond These Numbers?

Beyond the metrics above, investors comparing these three pharma and healthcare names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and factors specific to the segment such as regulatory approvals, export orders, raw material costs and the gap between reported profit and cash generation. A single-quarter snapshot can shift quickly, and smaller companies in particular can show wide swings from one quarter to the next.

It also helps to read the latest quarterly filings and investor presentations of Fredun Pharmaceuticals, DIL and Themis Medicare directly, since the figures here come from standardised data and do not capture company-specific context such as one-time items, order timing or promoter actions.

Conclusion

Fredun Pharmaceuticals vs DIL vs Themis Medicare highlights how differently three companies in the same pharma and healthcare segment can look across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.

FAQs on Fredun Pharmaceuticals vs DIL vs Themis Medicare

What is the market cap difference between Fredun Pharmaceuticals, DIL and Themis Medicare?

Ans. As of October 2026, Fredun Pharmaceuticals has a market cap of approximately Rs 2,537 crore, DIL is at approximately Rs 1,583 crore, and Themis Medicare is at approximately Rs 1,006 crore.

What are the PE and PB ratios of Fredun Pharmaceuticals, DIL and Themis Medicare?

Ans. As of October 2026, the PE ratios stand at 57.90, 27.21 and 25.17 respectively, and the price to book ratios stand at 9.43, 3.89 and 2.75 respectively.

Which of the three has the highest ROE?

Ans. Fredun Pharmaceuticals, DIL and Themis Medicare post ROE of 11.73%, 17.67% and 0.42% respectively as of October 2026. DIL has the highest return on equity of the three at 17.67%, while Themis Medicare has the lowest at 0.42%.

Which of these three stocks pays the highest dividend yield?

Ans. Fredun Pharmaceuticals, DIL and Themis Medicare carry dividend yields of 0.02%, 0.68% and 0.46% respectively.

What is the debt to equity ratio for Fredun Pharmaceuticals, DIL and Themis Medicare?

Ans. Fredun Pharmaceuticals carries a debt to equity of 0.80, DIL of 0.28, and Themis Medicare of 0.25.

What were the latest quarterly revenue and net profit of Fredun Pharmaceuticals, DIL and Themis Medicare?

Ans. For Q1 FY27 (quarter ended June 2026), Fredun Pharmaceuticals reported revenue of Rs 228.25 crore and net profit of Rs 13.13 crore, DIL reported revenue of Rs 126.19 crore and net profit of Rs 9.53 crore, and Themis Medicare reported revenue of Rs 87.95 crore and net profit of Rs 24.61 crore.

Does this comparison recommend one of Fredun Pharmaceuticals, DIL and Themis Medicare?

Ans. This comparison does not declare one stock ahead of another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor's own criteria and research.